-
1.发明申请USE OF LYSOSOMAL CARBOXYPEPTIDASE C (PRCP) AS A THERAPEUTIC OR DIAGNOSTIC TARGET 审中-公开作为治疗或诊断性目标的骨质疏松性羧肽酶C（PRCP）的使用公开(公告)号：US20110033844A1
公开(公告)日：2011-02-10
申请号：US12303718
申请日：2007-05-25
申请人： Stefan Golz , Ulf Brüggemeier , Adreas Geerts
发明人： Stefan Golz , Ulf Brüggemeier , Adreas Geerts
IPC分类号： C12Q1/68 , G01N33/566
CPC分类号： G01N33/57438 , G01N2333/948
摘要： The invention provides a human PRCP which is associated with the cardiovascular diseases, hematological diseases, neurological diseases and cancer. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases and cancer. The invention also features compounds which bind to and/or activate or inhibit the activity of PRCP as well as pharmaceutical compositions comprising such compounds.
摘要翻译： 本发明提供了与心血管疾病，血液疾病，神经疾病和癌症有关的人类PRCP。 本发明还提供了用于鉴定可用于治疗或预防心血管疾病，血液疾病，神经疾病和癌症的化合物的测定。 本发明还涉及结合和/或活化或抑制PRCP的活性的化合物以及包含这些化合物的药物组合物。
-
2.发明申请Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 2a receptor (5ht2a) 审中-公开与5-羟色胺2a受体（5ht2a）相关疾病的诊断和治疗公开(公告)号：US20090311242A1
公开(公告)日：2009-12-17
申请号：US11658843
申请日：2005-07-18
申请人： Stefan Golz , Ulf Brüggemeier , Andreas Geerts
发明人： Stefan Golz , Ulf Brüggemeier , Andreas Geerts
IPC分类号： A61K39/395 , G01N33/567 , C12Q1/68 , A61K31/7088 , A61K38/00
CPC分类号： G01N33/566 , G01N2333/726 , G01N2500/04
摘要： The invention provides a human 5HT2a which is associated with the cardiovascular diseases, respiratory diseases, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, respiratory diseases, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of 5HT2a as well as pharmaceutical compositions comprising such compounds.
摘要翻译： 本发明提供了与心血管疾病，呼吸系统疾病，皮肤病，胃肠疾病，癌症，炎症，代谢疾病，血液病，肌肉骨骼疾病，神经系统疾病，泌尿系疾病有关的人5HT2a。 本发明还提供了用于鉴定可用于治疗或预防心血管疾病，呼吸系统疾病，皮肤病，胃肠疾病，癌症，炎症，代谢疾病，血液病，肌肉骨骼疾病，神经系统疾病，泌尿系疾病的化合物的测定。 本发明还涉及结合和/或活化或抑制5HT2a活性的化合物以及包含这些化合物的药物组合物。
-
3.发明授权Diagnostics and therapeutics for diseases associated with Neuromedin U2 receptor (NMU2) 失效与神经介肽U2受体（NMU2）相关疾病的诊断和治疗公开(公告)号：US07491550B2
公开(公告)日：2009-02-17
申请号：US10515966
申请日：2003-05-14
申请人： Stefan Golz , Ulf Brüggemeier , Andreas Geerts
发明人： Stefan Golz , Ulf Brüggemeier , Andreas Geerts
IPC分类号： G01N33/566 , C07K1/00
CPC分类号： G01N33/6893 , A61K38/11 , G01N33/566 , G01N2500/04
摘要： The invention provides a human NMU2 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of NMU2 as well as pharmaceutical compositions comprising such compounds.
摘要翻译： 本发明提供了与血液疾病，心血管疾病，外周和中枢神经系统疾病，癌症，泌尿生殖系疾病和呼吸系统疾病相关的人NMU2。 本发明还提供了用于鉴定可用于治疗或预防血液疾病，心血管疾病，外周和中枢神经系统疾病，癌症，泌尿生殖疾病和呼吸系统疾病的化合物的测定。 本发明还涉及结合和/或活化或抑制NMU2的活性的化合物以及包含这些化合物的药物组合物。
-
公开(公告)号：US08088584B2
公开(公告)日：2012-01-03
申请号：US12444596
申请日：2007-10-02
申请人： Stefan Golz , Holger Summer , Andreas Geerts , Ulf Brüggemeier , Barbara Albrecht-Küpper , Martina Klein , Sonja Steppan , Peter Ellinghaus , Donatella D'Urso , Michael Seewald , Hendrik Milting
发明人： Stefan Golz , Holger Summer , Andreas Geerts , Ulf Brüggemeier , Barbara Albrecht-Küpper , Martina Klein , Sonja Steppan , Peter Ellinghaus , Donatella D'Urso , Michael Seewald , Hendrik Milting
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , Y10S530/841
摘要： The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.
摘要翻译： 本发明提供了与心血管疾病，血液疾病，神经疾病，癌症，内分泌疾病和泌尿系疾病相关的LTBP2。 本发明还提供了用于鉴定可用于治疗或预防心血管疾病，血液疾病，神经疾病，癌症，内分泌疾病和泌尿系统疾病的化合物的测定。 本发明还涉及结合和/或活化或抑制LTBP2的活性的化合物以及包含这些化合物的药物组合物。 本发明还提供LTBP2作为心血管疾病，血液疾病，神经疾病，癌症，内分泌疾病和泌尿系疾病等疾病的生物标志物。
-
5.发明授权公开(公告)号：US07803593B2
公开(公告)日：2010-09-28
申请号：US10573500
申请日：2004-09-16
CPC分类号： C07K16/40 , C12N9/1029
摘要： The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds.
摘要翻译： 本发明涉及新的酰基甘油酰基转移酶样蛋白MGAT-X1的多核苷酸序列。 本发明还提供了与皮肤病，泌尿疾病，肌肉骨骼疾病，血液疾病，癌症，繁殖障碍，神经疾病，代谢疾病，心血管疾病或胃肠疾病有关的人MGAT-X1。 本发明还提供了用于鉴定可用于调节皮肤病，泌尿系统疾病，肌肉骨骼疾病，血液疾病，癌症，繁殖障碍，神经疾病，代谢疾病，心血管疾病或用于治疗这些疾病的胃肠病学疾病的化合物的测定 与MGAT-X1的表达相关。 本发明还涉及结合和/或活化或抑制MGAT-X1的活性的化合物以及包含这些化合物的药物组合物。
-
公开(公告)号：US20100104501A1
公开(公告)日：2010-04-29
申请号：US12445494
申请日：2007-10-02
申请人： Stefan Golz , Holger Summer , Andreas Geerts , Ulf Brüggemeier , Barbara Albrecht , Martina Klein , Sonja Steppan , Peter Ellinghaus , Donatella D'urso , Michael Seewald , Hendrik Milting
发明人： Stefan Golz , Holger Summer , Andreas Geerts , Ulf Brüggemeier , Barbara Albrecht , Martina Klein , Sonja Steppan , Peter Ellinghaus , Donatella D'urso , Michael Seewald , Hendrik Milting
CPC分类号： G01N33/573 , C12Q1/37 , G01N2333/948
摘要： The invention provides PRSS23, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PRSS23 as well as pharmaceutical compositions comprising such compounds. The invention also provides PRSS23 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.
摘要翻译： 本发明提供了与心血管疾病，血液疾病，神经疾病，癌症，内分泌疾病和泌尿系疾病有关的PRSS23。 本发明还提供了用于鉴定可用于治疗或预防心血管疾病，血液疾病，神经疾病，癌症，内分泌疾病和泌尿系统疾病的化合物的测定。 本发明还涉及结合和/或活化或抑制PRSS23的活性的化合物以及包含这些化合物的药物组合物。 本发明还提供了PRSS23作为心血管疾病，血液病，神经疾病，癌症，内分泌疾病和泌尿系疾病等疾病的生物标志物。
-
7.发明授权Diagnostics and therapeutics for diseases associated with G-protein coupled receptor AdipoR1(AdipoR1) 有权与G蛋白偶联受体AdipoR1（AdipoR1）相关疾病的诊断和治疗公开(公告)号：US08252525B2
公开(公告)日：2012-08-28
申请号：US10572883
申请日：2004-09-16
申请人： Stefan Golz , Ulf Brüggemeier , Andreas Geerts
发明人： Stefan Golz , Ulf Brüggemeier , Andreas Geerts
IPC分类号： C12Q1/68
CPC分类号： G01N33/6893 , G01N33/74 , G01N2800/32
摘要： The invention provides a human AdipoR1 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, inflammation, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, inflammation, respiratory diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of AdipoR1 as well as pharmaceutical compositions comprising such compounds.
摘要翻译： 本发明提供了与心血管疾病，皮肤病，胃肠疾病，癌症，血液疾病，炎症，呼吸系统疾病，神经系统疾病和泌尿系疾病相关的人AdipoR1。 本发明还提供了用于鉴定可用于治疗或预防心血管疾病，皮肤病，胃肠疾病，癌症，血液疾病，炎症，呼吸系统疾病，神经疾病和泌尿疾病的化合物的测定。 本发明还具有结合和/或活化或抑制AdipoR1活性的化合物以及包含这些化合物的药物组合物。
-
公开(公告)号：US20100028264A1
公开(公告)日：2010-02-04
申请号：US12444596
申请日：2007-10-02
申请人： Stefan Golz , Holger Summer , Andreas Geerts , Ulf Brüggemeier , Barbara Albrecht-Küpper , Martina Klein , Sonja Steppan , Peter Ellinghaus , Donatella D'Urso , Michael Seewald , Hendrik Milting
发明人： Stefan Golz , Holger Summer , Andreas Geerts , Ulf Brüggemeier , Barbara Albrecht-Küpper , Martina Klein , Sonja Steppan , Peter Ellinghaus , Donatella D'Urso , Michael Seewald , Hendrik Milting
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , Y10S530/841
摘要： The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.
摘要翻译： 本发明提供了与心血管疾病，血液疾病，神经疾病，癌症，内分泌疾病和泌尿系疾病相关的LTBP2。 本发明还提供了用于鉴定可用于治疗或预防心血管疾病，血液疾病，神经疾病，癌症，内分泌疾病和泌尿系统疾病的化合物的测定。 本发明还涉及结合和/或活化或抑制LTBP2的活性的化合物以及包含这些化合物的药物组合物。 本发明还提供LTBP2作为心血管疾病，血液疾病，神经疾病，癌症，内分泌疾病和泌尿系疾病等疾病的生物标志物。
-
9.发明申请ACYLGLYCEROL ACETYLTRANSFERASE-LIKE PROTEIN MGAT-X1 AND USES THEREOF 失效ACYLGLYCEROL乙酰胆碱酯酶蛋白MGAT-X1及其用途公开(公告)号：US20110086013A1
公开(公告)日：2011-04-14
申请号：US12854524
申请日：2010-08-31
CPC分类号： C07K16/40 , C12N9/1029
摘要： The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds.
摘要翻译： 本发明涉及新的酰基甘油酰基转移酶样蛋白MGAT-X1的多核苷酸序列。 本发明还提供了与皮肤病，泌尿疾病，肌肉骨骼疾病，血液疾病，癌症，繁殖障碍，神经疾病，代谢疾病，心血管疾病或胃肠疾病有关的人MGAT-X1。 本发明还提供了用于鉴定可用于调节皮肤病，泌尿系统疾病，肌肉骨骼疾病，血液疾病，癌症，繁殖障碍，神经疾病，代谢疾病，心血管疾病或用于治疗这些疾病的胃肠病学疾病的化合物的测定 与MGAT-X1的表达相关。 本发明还涉及结合和/或活化或抑制MGAT-X1的活性的化合物以及包含这些化合物的药物组合物。
-
10.发明授权Methods of screening for potential therapeutics for diseases associated with G-protein coupled receptor HM74a 失效筛选与G蛋白偶联受体HM74a相关疾病的潜在治疗方法公开(公告)号：US07465548B2
公开(公告)日：2008-12-16
申请号：US10544615
申请日：2004-02-05
申请人： Stefan Golz , Ulf Brüggemeier , Holger Summer
发明人： Stefan Golz , Ulf Brüggemeier , Holger Summer
IPC分类号： G01N33/53 , G01N33/567 , A61K49/00
CPC分类号： G01N33/566 , A61K38/177 , G01N33/74 , G01N2333/726 , G01N2500/00
摘要： The invention provides a human HM74a which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, cancer, inflammation, urological diseases, respiratory diseases and gastroenterological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, cancer, inflammation, urological diseases, respiratory diseases and gastroenterological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of HM74a as well as pharmaceutical compositions comprising such compounds.
摘要翻译： 本发明提供了与周围和中枢神经系统疾病，心血管疾病，血液疾病，癌症，炎症，泌尿科疾病，呼吸系统疾病和胃肠疾病相关的人类HM74a。 本发明还提供了用于鉴定可用于治疗或预防外周和中枢神经系统疾病，心血管疾病，血液疾病，癌症，炎症，泌尿科疾病，呼吸系统疾病和胃肠疾病的化合物的化合物。 本发明还涉及结合和/或活化或抑制HM74a的活性的化合物以及包含这些化合物的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
26 条记录 (耗时 0.038 秒)
